TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02729051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI
Description: This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UMEC
Description: This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
Study: NCT04274673

Intervention type: DEVICE
Group type: OTHER
Intervention: measuring cotinine level
Description: Measuring of the cotinine levels

Intervention type: DEVICE
Group type: OTHER
Intervention: measuring cotinine level
Description: Measuring of the cotinine levels
Study: NCT01295450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apevinat BC
Description: Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin Complex
Description: A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
Study: NCT02087631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate
Description: Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
Study: NCT00651456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy (Pemetrexed and Cisplatin)
Description: * Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
Description: * Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)
Study: NCT03209804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hybrid operating techniques
Description: A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hybrid operating techniques
Description: A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
Study: NCT04840810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-plane Axis
Description: In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Out of plane Axis
Description: In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis.
Study: NCT01903850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spray cryotherapy
Description: spray cryotherapy
Study: NCT00262587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled sugar powder in a placebo inhaler
Study: NCT03124979

Intervention type: DEVICE
Group type: OTHER
Intervention: LNCS DBI Sensor
Description: Noninvasive Measurement of SpO2
Study: NCT04160325

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: postoperative 3-month exclusive enteral nutrition
Description: postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: azathioprine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Description: azathioprine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal diet
Description: normal diet
Study: NCT04459390

Intervention type: DIAGNOSTIC_TEST
Intervention: realtime PCR
Description: Detection of SARS-CoV-2 genes by realtime PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: realtime PCR
Description: Detection of SARS-CoV-2 genes by realtime PCR
Study: NCT00377403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Intervention drug:~Dose: 500mg tid for 10 days
Study: NCT02034799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioseal Fibrin Sealant

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Study: NCT01682174

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Drink
Study: NCT02070848

Intervention type: OTHER
Intervention: Session 1-4
Description: Familiarization sessions to knee-extensor exercise separated by 72h recovery

Intervention type: OTHER
Intervention: Session 4
Description: After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
Study: NCT00377403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide with guaifenesin
Description: Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan hydrobromide with guaifenesin
Description: Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Description: Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guaifenesin
Description: Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine Sustained Action
Description: Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine Sustained Action
Description: Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline spray (0.65%)
Description: Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray (0.65%)
Description: Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion
Study: NCT01746004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY2157299
Description: \[\^14C\]-LY2157299 monohydrate administered as oral solution
Study: NCT04305314

Intervention type: OTHER
Intervention: PRI (Enhanced Recovery after surgery protocol)
Description: Standard use of Spanish perioperative guidelines (PRI)
Study: NCT02541890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work place intervention
Description: Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
Study: NCT01372306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reminyl
Description: Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reminyl
Description: Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
Study: NCT03785561

Intervention type: OTHER
Intervention: participation in a health research study
Description: Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital
Study: NCT01473667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Cervical Plexus Block (SCP) block
Description: SCP block using 10-15ml of 1% Ropivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local site infiltration
Description: Local site infiltration using 2% lidocaine
Study: NCT01753921

Intervention type: OTHER
Intervention: this is not an intervention study
Description: Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.

Intervention type: OTHER
Intervention: this is not an intervention study
Description: Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.

Intervention type: OTHER
Intervention: this is not an intervention study
Description: Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.

Intervention type: OTHER
Intervention: this is not an intervention study
Description: Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.

Intervention type: DEVICE
Intervention: MRI
Description: MRI study of the brain will be performed at t=3months.

Intervention type: DEVICE
Intervention: MRI
Description: MRI study of the brain will be performed at t=3months.
Study: NCT03434938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: MI sessions' goals will to obtain patients' collaboration, creating a shared tailored approach to complement the individual geriatric rehabilitation plan, and reinforcing engagement and adherence at 3 months.~All 20-minutes sessions will follow the logical sequence of MI by Rollnick and Millner (engaging, focusing, evoking and planning) in a semi-structured format to ensure homogeneity. Content will include: 1) Creating engagement with patients by exploring their preferences, values, goals, and their knowledge and expectations about rehabilitation and recovery, 2) enhancing motivation by evoking patients' strengths and abilities, 3) follow-up and reinforcement, and 4) adapting the plan to the improved abilities and to home setting after discharge.
Study: NCT05717556

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Jugular Vein Catheterization
Description: Inserting a cannula into the internal jugular vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Jugular Vein Catheterization
Description: Inserting a cannula into the internal jugular vein
Study: NCT01955954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canary Breathing System
Description: The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of abnormal breathing patterns.
Study: NCT00276640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine, carboplatin
Description: vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine, carboplatin, etoposide
Description: vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks
Study: NCT05959993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human Care Model Based Nursing Interventions
Description: The interviews scheduled for the intervention group were organized in accordance with the sub-dimensions of the PAIS-SR scale, and the content of each interview was informed by the 10 improvement processes of HCT.
Study: NCT00914329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelsemium Sempervirens
Description: 5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelsemium Sempervirens
Description: 15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Study: NCT02070848

Intervention type: OTHER
Intervention: Session 5
Description: 2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
Study: NCT03699709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Budgeting, purchasing and cooking educational intervention
Description: Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
Study: NCT02729051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
Study: NCT02002780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day Camp
Description: The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project.
Study: NCT01338636

Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan
Description: 5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
Study: NCT03316937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Types of scalers
Description: Scaling
Study: NCT00540124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.2 mg once a day
Study: NCT03219840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum
Description: All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Study: NCT01046539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RDC-0313 + Buprenorphine
Description: 1 and 4 mg (1 dose for each) + 8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg
Study: NCT02164877

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pectin
Description: Patients allocated to experiment group will receive 15g pectin each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pectin
Description: Patients allocated to experiment group will receive 15g pectin each day
Study: NCT03599349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound w/ visualization
Study: NCT01862705

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thoracic spine manipulation
Description: TSM thrust or non-thrust

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic spine manipulation
Description: TSM thrust or non-thrust
Study: NCT00331643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study: NCT03369379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D3 Vitamin
Description: Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT01337895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dairy
Description: No more than 1 serving per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dairy
Description: 4 or more servings per day
Study: NCT03278262

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
Study: NCT00504426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-249
Description: 1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-249
Description: 1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-249
Description: 1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-249
Description: 1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
Study: NCT04791501

Intervention type: DEVICE
Intervention: Mechanical ventilation
Description: Ventilatory support
Study: NCT01560039

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: EEG neurofeedback based on the primary motor cortex

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: Sham EEG neurofeedback
Study: NCT02605629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CG428
Description: The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.